Treatment of malignant pericardial effusion with 32P-colloid.
Malignant pericardial effusion is usually treated only when signs of cardiac tamponade develop. Several methods of treatment have been reported with an overall response rate of approximately 75%. Since our initial study using intrapericardial 32P-colloid instillation as a treatment modality for pericardial effusion demonstrated a significant higher response rate, this study was conducted to further evaluate the efficacy of intrapericardial 32P-colloid in terms of response rates and duration of remissions. Intrapericardial instillation of 185-370 MBq (5-10 mCi) 32P-colloid in 36 patients with malignant pericardial effusion resulted in a complete remission rate of 94.5% (34 patients) whereas two patients did not respond to treatment due to a foudroyant formation of pericardial fluid. The median duration time was 8 months. No side-effects were observed. These results suggest that intrapericardial instillation of 32P-colloid is a simple, reliable and safe treatment strategy for patients with malignant pericardial effusions. Therefore, since further evidence is provided that 32P-colloid is significantly more effective than external radiation or non-radioactive sclerosing agents, this treatment modality should be considered for the management of malignant pericardial effusion.
Dempke
W
W
Martin-Luther-University Halle-Wittenberg, Department of Internal Medicine IV, Halle, Germany.
Firusian
N
N
D001943:Breast Neoplasms / Q000473:pathology; D002305:Cardiac Tamponade / Q000209:etiology / Q000503:physiopathology; D017608:Chromium Compounds / Q000627:therapeutic use*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000473:pathology; D006801:Humans; D007322:Instillation, Drug; D008175:Lung Neoplasms / Q000473:pathology; D008223:Lymphoma / Q000473:pathology; D009369:Neoplasms / Q000150:complications / Q000473:pathology* / Q000532:radiotherapy; D010490:Pericardial Effusion / Q000209:etiology / Q000532:radiotherapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000627:therapeutic use*
D017608:Chromium Compounds; D010761:Phosphorus Radioisotopes; D019275:Radiopharmaceuticals